Home Merck Announces First-Quarter 2013 Financial Results
 

Keywords :   


Merck Announces First-Quarter 2013 Financial Results

2013-05-01 13:00:00| Merck.com - Corporate News

Dateline City:  WHITEHOUSE STATION, N.J. 2013 First-Quarter Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.52 Worldwide Sales were $10.7 Billion, a Decrease of 9 Percent Primarily as a Result of Patent Expiries, and Including a 2 Percent Unfavorable Impact from Foreign Exchange Growth in Vaccines, Immunology, HIV, Animal Health and Consumer Care Products Received Breakthrough Therapy Designation for Lambrolizumab, an Investigational Candidate for Advanced Melanoma; Five Products Currently Under Regulatory Review Announced New $15 Billion Share Repurchase Program; Plans to Repurchase Approximately $7.5 Billion of Common Stock over the Next Twelve Months Revises 2013 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Revises GAAP EPS Range to $1.92 to $2.16 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2013.     $ in millions, except EPS amounts   FirstQuarter2013   FirstQuarter2012 Language:  English Contact HTML:  MerckMedia Contacts:Steve Cragle, 908-423-3461Kelley Dougherty, 908-423-4291orInvestor Contacts:Carol Ferguson, 908-423-4465Alex Kelly, 908-423-5185 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: results financial announces merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.11
25.11 122
25.11PA YAMAHAag03
25.11
25.11 13
25.11DX Z 50th Anniversary Ver.
25.11 11
25.11CUPRUM LUBIN
More »